|
1
|
Bui AL, Horwich TB and Fonarow GC:
Epidemiology and risk profile of heart failure. Nat Rev Cardiol.
8:30–41. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vos T, Flaxman AD, Naghavi M, Lozano R,
Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V,
et al: Years lived with disability (YLDs) for 1160 sequelae of 289
diseases and injuries 1990–2010: A systematic analysis for the
Global Burden of Disease Study 2010. Lancet. 380:2163–2196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raso A, Dirkx E, Philippen LE,
Fernandez-Celis A, De Majo F, Sampaio-Pinto V, Sansonetti M, Juni
R, El Azzouzi H, Calore M, et al: Therapeutic Delivery of miR-148a
Suppresses Ventricular Dilation in Heart Failure. Mol Ther.
27:584–599. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Timmis A, Townsend N, Gale C, Grobbee R,
Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, et al
ESC Scientific Document Group, : European Society of Cardiology:
Cardiovascular Disease Statistics 2017. Eur Heart J. 39:508–579.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu C, Yang CX, Chen XR, Liu BX, Li Y,
Wang XZ, Sun W, Li P and Kong XQ: Alamandine attenuates
hypertension and cardiac hypertrophy in hypertensive rats. Amino
Acids. 50:1071–1081. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Liu C, Chen X and Li P: Alamandine
attenuates long term hypertension induced cardiac fibrosis
independent of blood pressure. Mol Med Rep. 19:4553–4560.
2019.PubMed/NCBI
|
|
7
|
Yue Y, Meng K, Pu Y and Zhang X:
Transforming growth factor beta (TGF-β) mediates cardiac fibrosis
and induces diabetic cardiomyopathy. Diabetes Res Clin Pract.
133:124–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan X, Pan J, Wen L, Gong B, Li J, Gao H,
Tan W, Liang S, Zhang H and Wang X: miR-144-3p Enhances Cardiac
Fibrosis After Myocardial Infarction by Targeting PTEN. Front Cell
Dev Biol. 7:2492019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rai R, Sun T, Ramirez V, Lux E, Eren M,
Vaughan DE and Ghosh AK: Acetyltransferase p300 inhibitor reverses
hypertension-induced cardiac fibrosis. J Cell Mol Med.
23:3026–3031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan CY, Wong JX, Chan PS, Tan H, Liao D,
Chen W, Tan LW, Ackers-Johnson M, Wakimoto H, Seidman JG, et al:
Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis
Through Regulation of Bmp7 and Ctgf. Circ Res. 125:834–846. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu QQ, Xu YJ, Yang C, Tang Y, Li L, Cai
HB, Hou BN, Chen HF, Wang Q, Shi XG, et al: Sodium Tanshinone IIA
Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via
Improving Cholinergic System. BioMed Res Int. 2016:98525362016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Q, Shen L, Wang Z, Jiang HP and Liu LX:
Tanshinone IIA protects against myocardial ischemia reperfusion
injury by activating the PI3K/Akt/mTOR signaling pathway. Biomed
Pharmacother. 84:106–114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang
J and Wang W: Potential anticancer activity of tanshinone IIA
against human breast cancer. Int J Cancer. 116:799–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Han X, Zhang H, Wu J and Li B: The
interplay between autophagy and apoptosis induced by tanshinone IIA
in prostate cancer cells. Tumour Biol. 37:7667–7674. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao S, Liu Z, Li H, Little PJ, Liu P and
Xu S: Cardiovascular actions and therapeutic potential of
tanshinone IIA. Atherosclerosis. 220:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen FY, Guo R and Zhang BK: Advances in
cardiovascular effects of tanshinone II(A). Zhongguo Zhong Yao Za
Zhi. 40:1649–1653. 2015.(In Chinese). PubMed/NCBI
|
|
17
|
Sag CM, Santos CX and Shah AM: Redox
regulation of cardiac hypertrophy. J Mol Cell Cardiol. 73:103–111.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Madamanchi NR and Runge MS: Redox
signaling in cardiovascular health and disease. Free Radic Biol
Med. 61:473–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bonnefont-Rousselot D, Mahmoudi A,
Mougenot N, Varoquaux O, Le Nahour G, Fouret P and Lechat P:
Catecholamine effects on cardiac remodelling, oxidative stress and
fibrosis in experimental heart failure. Redox Rep. 7:145–151. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan SH, Zhao NW, Geng ZR, Shen JY, Liu FM,
Yan D, Zhou J, Nie C, Huang CC and Fang ZY: Modulations of
Keap1-Nrf2 signaling axis by TIIA ameliorated the oxidative
stress-induced myocardial apoptosis. Free Radic Biol Med.
115:191–201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gan XB, Duan YC, Xiong XQ, Li P, Cui BP,
Gao XY and Zhu GQ: Inhibition of cardiac sympathetic afferent
reflex and sympathetic activity by baroreceptor and vagal afferent
inputs in chronic heart failure. PLoS One. 6:e257842011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Wang Q, Wang X, Chen X, Shao M,
Zhang Q, Guo D, Wu Y, Li C, Wang W, et al: Tanshinone IIA protects
against heart failure post-myocardial infarction via
AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother.
112:1085992019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koshman YE, Patel N, Chu M, Iyengar R, Kim
T, Ersahin C, Lewis W, Heroux A and Samarel AM: Regulation of
connective tissue growth factor gene expression and fibrosis in
human heart failure. J Card Fail. 19:283–294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hou L, Guo J, Xu F, Weng X, Yue W and Ge
J: Cardiomyocyte dimethylarginine dimethylaminohydrolase1
attenuates left-ventricular remodeling after acute myocardial
infarction: Involvement in oxidative stress and apoptosis. Basic
Res Cardiol. 113:282018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Zhang S and Chen X: Tanshinone
IIA protects against cardiac fibrosis through inhibition of
β-tubulin expression. J Biol Regul Homeost Agents. 32:1451–1455.
2018.PubMed/NCBI
|
|
27
|
Tsai YT, Loh SH, Lee CY, Lee SP, Chen YL,
Cheng TH and Tsai CS: Tanshinone IIA Inhibits High Glucose-Induced
Collagen Synthesis via Nuclear Factor Erythroid 2-Related Factor 2
in Cardiac Fibroblasts. Cell Physiol Biochem. 51:2250–2261. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kura B, Szeiffova Bacova B, Kalocayova B,
Sykora M and Slezak J: Oxidative Stress-Responsive MicroRNAs in
Heart Injury. Int J Mol Sci. 21:3582020. View Article : Google Scholar
|
|
29
|
Kim H, Yun J and Kwon SM: Therapeutic
Strategies for Oxidative Stress-Related Cardiovascular Diseases:
Removal of Excess Reactive Oxygen Species in Adult Stem Cells. Oxid
Med Cell Longev. 2016:24831632016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Snezhkina AV, Kudryavtseva AV, Kardymon
OL, Savvateeva MV, Melnikova NV, Krasnov GS and Dmitriev AA: ROS
Generation and Antioxidant Defense Systems in Normal and Malignant
Cells. Oxid Med Cell Longev. 2019:61758042019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Honda T, Hirakawa Y and Nangaku M: The
role of oxidative stress and hypoxia in renal disease. Kidney Res
Clin Pract. 38:414–426. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kura B, Szeiffova Bacova B, Kalocayova B,
Sykora M and Slezak J: Oxidative Stress-Responsive MicroRNAs in
Heart Injury. Int J Mol Sci. 21:3582020. View Article : Google Scholar
|
|
33
|
Chen T, Li M, Fan X, Cheng J and Wang L:
Sodium Tanshinone IIA Sulfonate Prevents Angiotensin II–Induced
Differentiation of Human Atrial Fibroblasts into Myofibroblasts.
Oxid Med Cell Longev. 2018:67125852018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang P, Zhou S, Xu L, Lu Y, Yuan X, Zhang
H, Li R, Fang J and Liu P: Hydrogen peroxide-mediated oxidative
stress and collagen synthesis in cardiac fibroblasts: Blockade by
tanshinone IIA. J Ethnopharmacol. 145:152–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang P, Wu X, Bao Y, Fang J, Zhou S, Gao
J, Pi R, Mou YG and Liu P: Tanshinone IIA prevents cardiac
remodeling through attenuating NAD (P)H oxidase-derived reactive
oxygen species production in hypertensive rats. Pharmazie.
66:517–524. 2011.PubMed/NCBI
|
|
36
|
Huang L, Zhu J, Zheng M, Zou R, Zhou Y and
Zhu M: Tanshinone IIA protects against subclinical
lipopolysaccharide induced cardiac fibrosis in mice through
inhibition of NADPH oxidase. Int Immunopharmacol. 60:59–63. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu DM, Wang YJ, Han XR, Wen X, Li L, Xu L,
Lu J and Zheng YL: Tanshinone IIA prevents left ventricular
remodelling via the TLR4/MyD88/NF-κB signalling pathway in rats
with myocardial infarction. J Cell Mol Med. 22:3058–3072. 2018.
View Article : Google Scholar : PubMed/NCBI
|
